A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1)–targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fessas, Petros, Lee, Hassal, Ikemizu, Shinji, Janowitz, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612055/
https://www.ncbi.nlm.nih.gov/pubmed/28923212
http://dx.doi.org/10.1053/j.seminoncol.2017.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612055/
https://www.ncbi.nlm.nih.gov/pubmed/28923212
http://dx.doi.org/10.1053/j.seminoncol.2017.06.002

Ejemplares similares